Journal of Antivirals & Antiretrovirals
Open Access
ISSN: 1948-5964
ISSN: 1948-5964
Rasha El Baz,Thuong H. Tran, Andrea Cuconati, James Arthos, Pooja Jain, and Zafar K. Khan
Posters: JAA
The current antiretroviral therapy (HAART) has several disadvantages including renal and hepatic toxicity as well as high cost. Measures are being undertaken for ARV therapy alternatives, particularly for the control of early HIV-1 infection. Dendritic cells (DCs) present in the mucosal tissue, together with CD4+ T lymphocytes and macrophages, are among the fi rst cells to encounter HIV-1. Th e dendritic cell-specifi c intercellular adhesion molecule-3- grabbing non-integrin (DC-SIGN) molecule plays a crucial role in binding HIV-1 through the high affi nity interaction with viral envelope glycoprotein gp120. DC-SIGN, a mannose-binding C-type lectin expressed on cells in the mucosal tissue of the rectum, uterus and cervix, facilitates early HIV-1 infection aft er sexual transmission. Th e study present herein reports a novel, specifi c and optimized high-throughput screening assay capable of quantifying the binding as well as the inhibition of DC-SIGN and gp120. First, the assay?s linearity was established as it was miniaturized from a 96 to a 384 well format. Assay specifi city was then determined through competitive inhibition while optimization occurred for DMSO tolerability (0.5%), Z? Factor (0.51), S/N (3.26) and CV% (5.1%). Previously recognized antagonists of DC-SIGN/gp120 binding were tested for assay validation to prove that it could detect inhibition. In conclusion, the assay was deemed ready for the high-throughput screening of potential agents that block the binding between these proteins so that they may be formulated into drugs that prevent early HIV-1 infection.